External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Inflammatory Disease CCC 2025
Roche and Genentech at

CCC 2025

February 06 - February 08
San Francisco, USA
ccc2025.in
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Feb 7 / Roche and Genentech
RO7790121 demonstrates early clinical response and symptom improvement - results from the Phase IIB TUSCANY-2 trial in moderately to severely active ulcerative colitis
Results from the exploratory endpoint of clinical response and patient reported outcomes of rectal bleeding and stool frequency from the TUSCANY-2 trial. This was a randomised, double-blind, placebo-controlled, dose-ranging Phase IIb study of RO7790121, an antibody against tumour necrosis factor like ligand 1A (anti-TL1A) in adults with moderately to severely active ulcerative colitis.
Inflammatory Disease Inflammatory Bowel Disease CCC-2025
01:00 AM
Duration 90mins San Francisco, USA
RO7790121 demonstrates early clinical response and symptom improvement - results from the Phase IIB TUSCANY-2 trial in moderately to severely active ulcerative colitis
Allegretti JR, Yarur A, Feagan B, Danese S, Schreiber S, Peyrin-Biroulet L, Kierkus J, Leong RW, Bojic D, Lasch K, Schiffman C, Jairath V
Inflammatory Disease | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.